AP2781A - Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechansim, from the use of these porteins or from the inhibition thereof - Google Patents

Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechansim, from the use of these porteins or from the inhibition thereof

Info

Publication number
AP2781A
AP2781A AP2009004857A AP2009004857A AP2781A AP 2781 A AP2781 A AP 2781A AP 2009004857 A AP2009004857 A AP 2009004857A AP 2009004857 A AP2009004857 A AP 2009004857A AP 2781 A AP2781 A AP 2781A
Authority
AP
ARIPO
Prior art keywords
porteins
mechansim
inhibition
therapeutic
derived
Prior art date
Application number
AP2009004857A
Other languages
English (en)
Other versions
AP2009004857A0 (en
Inventor
Beate Kehrel
Original Assignee
Hamburger Stiftung Zur Forderung Van Wissenschaft Und Kultur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10051983A external-priority patent/DE10051983A1/de
Priority claimed from DE2001148624 external-priority patent/DE10148624A1/de
Application filed by Hamburger Stiftung Zur Forderung Van Wissenschaft Und Kultur filed Critical Hamburger Stiftung Zur Forderung Van Wissenschaft Und Kultur
Publication of AP2009004857A0 publication Critical patent/AP2009004857A0/xx
Application granted granted Critical
Publication of AP2781A publication Critical patent/AP2781A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
AP2009004857A 2000-10-20 2001-10-19 Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechansim, from the use of these porteins or from the inhibition thereof AP2781A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10051983A DE10051983A1 (de) 2000-10-20 2000-10-20 Inhibierung der pathogenen Wirkung oxidierter Proteine
DE2001148624 DE10148624A1 (de) 2001-10-02 2001-10-02 Oxidierte Proteine - ihre biologische Wirkung, sowie therapeutische und diagnostische Maßnahmen, die sich aus dem Wirkmechanismus, dem Einsatz dieser Proteine oder deren Inhibierung ableiten
PCT/EP2001/012129 WO2002032445A2 (de) 2000-10-20 2001-10-19 Hemmung der interaktion zwischen oxidierte proteine und cd36 oder dessen wirkmechanismus

Publications (2)

Publication Number Publication Date
AP2009004857A0 AP2009004857A0 (en) 2009-06-30
AP2781A true AP2781A (en) 2013-10-31

Family

ID=26007431

Family Applications (2)

Application Number Title Priority Date Filing Date
AP2009004857A AP2781A (en) 2000-10-20 2001-10-19 Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechansim, from the use of these porteins or from the inhibition thereof
APAP/P/2003/002795A AP2034A (en) 2000-10-20 2001-10-19 Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof.

Family Applications After (1)

Application Number Title Priority Date Filing Date
APAP/P/2003/002795A AP2034A (en) 2000-10-20 2001-10-19 Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof.

Country Status (14)

Country Link
EP (2) EP1994941A3 (xx)
JP (1) JP4881535B2 (xx)
AP (2) AP2781A (xx)
AT (1) ATE406908T1 (xx)
AU (1) AU2002215032A1 (xx)
CA (1) CA2453140C (xx)
CY (1) CY1110418T1 (xx)
DE (1) DE50114289D1 (xx)
DK (1) DK1328289T3 (xx)
ES (1) ES2307662T3 (xx)
HK (1) HK1057857A1 (xx)
OA (1) OA12431A (xx)
PT (1) PT1328289E (xx)
WO (1) WO2002032445A2 (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2523357C (en) * 2003-04-25 2015-07-14 Hamburger Stiftung Zur Foerderung Von Wissenschaft Und Kultur Treatment of hi-virus infections with oxidised blood proteins
CA2947343C (en) 2005-09-16 2019-04-30 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
JP2010235447A (ja) * 2007-07-30 2010-10-21 Igaku Seibutsugaku Kenkyusho:Kk 炎症性サイトカインの抑制剤
DE102010043733A1 (de) 2010-11-10 2012-05-10 Oxprotect Gmbh Unbeladene PEGylierte Liposomen zur Verwendung als Arzneimittel zur Prophylaxe und Therapie von hämorrhagischen und thrombo- embolischen Erkrankungen
DE102011003936A1 (de) 2011-02-10 2012-08-16 Oxprotect Gmbh Verwendung von Proteinen/Peptiden, welche an GRP78 (BIP) binden, in Labormethoden zum Monitoring von Thrombozyten-Aggregationshemmern
DE102011003944A1 (de) 2011-02-10 2012-08-16 Oxprotect Gmbh Detektion und Entfernung von missgefalteten Proteinen/Peptiden
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004744A1 (en) * 1989-10-06 1991-04-18 The Beth Israel Hospital Association Methods and apparatus for treating disease states using oxidized lipoproteins
WO1991010684A1 (en) * 1990-01-08 1991-07-25 Schering Corporation Oxidized variants of gm-csf
WO1992001467A1 (en) * 1990-07-18 1992-02-06 The Beth Israel Hospital Association Method for treating viral infections using oxidized lipoproteins
US5192264A (en) * 1989-10-06 1993-03-09 The Beth Israel Hospital Association Methods and apparatus for treating disease states using oxidized lipoproteins
WO1997021443A1 (en) * 1995-12-14 1997-06-19 Mark Borisovich Balazovskiy Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof
WO1999049883A2 (en) * 1998-03-28 1999-10-07 The University Court Of The University Of Glasgow Oxidized thymosin beta 4

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3819923A1 (de) * 1988-06-11 1989-12-21 Behringwerke Ag Fibrin(ogen)derivate, verfahren zu ihrer herstellung und ihre verwendung
JPH09504797A (ja) 1993-11-08 1997-05-13 ペプチド デリバリー システムズ プロプリエタリイ リミテッド ラベルされた診断用組成物と，その使用方法
CA2294355C (en) 1997-06-20 2006-11-28 Leuven Research & Development Vzw Assays, antibodies, and standards for detection of oxidized and mda-modified low density lipoproteins
AU1243500A (en) * 1998-11-06 2000-05-29 Emory University Biomarkers for oxidative stress
DE10045047A1 (de) * 2000-09-12 2002-03-21 Beate Kehrel Arzneimittel enthaltend aktiviertes Antithrombin III

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004744A1 (en) * 1989-10-06 1991-04-18 The Beth Israel Hospital Association Methods and apparatus for treating disease states using oxidized lipoproteins
US5192264A (en) * 1989-10-06 1993-03-09 The Beth Israel Hospital Association Methods and apparatus for treating disease states using oxidized lipoproteins
WO1991010684A1 (en) * 1990-01-08 1991-07-25 Schering Corporation Oxidized variants of gm-csf
WO1992001467A1 (en) * 1990-07-18 1992-02-06 The Beth Israel Hospital Association Method for treating viral infections using oxidized lipoproteins
WO1997021443A1 (en) * 1995-12-14 1997-06-19 Mark Borisovich Balazovskiy Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof
WO1999049883A2 (en) * 1998-03-28 1999-10-07 The University Court Of The University Of Glasgow Oxidized thymosin beta 4

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAWSON DAVID W ET AL: "CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells." JOURNAL OF CELL BIOLOGY, Bd. 138, Nr. 3, 1997, Seiten 707-717, XP002215771 ISSN: 0021-9525 *

Also Published As

Publication number Publication date
CY1110418T1 (el) 2015-04-29
EP1994941A3 (de) 2012-07-25
EP1328289B1 (de) 2008-09-03
WO2002032445A2 (de) 2002-04-25
HK1057857A1 (en) 2004-04-23
AP2003002795A0 (en) 2003-06-30
DE50114289D1 (de) 2008-10-16
ATE406908T1 (de) 2008-09-15
DK1328289T3 (da) 2008-12-15
OA12431A (en) 2006-04-19
JP4881535B2 (ja) 2012-02-22
PT1328289E (pt) 2008-12-10
EP1328289A2 (de) 2003-07-23
AU2002215032A1 (en) 2002-04-29
EP1994941A2 (de) 2008-11-26
WO2002032445A3 (de) 2003-04-17
ES2307662T3 (es) 2008-12-01
JP2004511526A (ja) 2004-04-15
AP2034A (en) 2009-08-28
AP2009004857A0 (en) 2009-06-30
CA2453140C (en) 2016-01-05
CA2453140A1 (en) 2002-04-25

Similar Documents

Publication Publication Date Title
DE60233157D1 (de) Zweikammer-herzschrittmacher-system zur diagnose und behebung von arrhythmien
DE50011194D1 (de) Medizinisches Instrument zum Präparieren von Gewebe
ATE318590T1 (de) Arzneimittelkombinationen (z.b. chlorpromazin und pentamidin) zur therapie von neoplastischen erkrankungen
WO2002040634A3 (en) Expression miniarrays and uses thereof
AU2002243370A1 (en) Body supported activity and condition monitor
AU2002216273A1 (en) Proteins, genes and their use for diagnosis and treatment of kidney response
AU2002226690A1 (en) Drugs for the diagnosis of tissue-reproductive activity or the treatment of proliferative diseases
IL143699A0 (en) Use of polypeptides or nucleic acids for the diagnosis or treatment of skin disorders and wound healing and for the identification of pharmacologically active substances
NO20013507L (no) Blandinger for behandling av inflammatoriske reaksjoner
AU2002303261A8 (en) Gene brcc2 and diagnostic and therapeutic uses thereof
GB0019302D0 (en) Biological materials and the use thereof for the treatment of disease
AP2781A (en) Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechansim, from the use of these porteins or from the inhibition thereof
AU6425800A (en) Agents for the diagnosis, prognosis and treatment of malignant diseases
DK1353948T3 (da) Oplöselige biologiske analoge til bata-amyloidpeptid
MXPA03006776A (es) Uso de inhibidores de interleucina-18 para el tratamiento y/o prevencion de enfermedad cardiaca.
EP1200133A4 (en) HANDLING OF FABRIC OR ORGAN TYPE USING THE NOTCH WAY
ZA200203269B (en) Nucleic acids of the human ABC1 gene and their therapeutic and diagnostic application.
AU4204700A (en) Compounds and methods for the diagnosis and treatment of (b. microti) infection
AU2001233954A1 (en) Proteins, genes and their use for diagnosis and treatment of schizophrenia
AU2001240820A1 (en) Proteins, genes and their use for diagnosis and treatment of vascular dementia
AU2002322301A1 (en) Methods for the diagnosis and treatment of cardiac tissue rejection
WO2000063348A3 (fr) Composition pharmaceutique comprenant des cellules nkt activees par des pim, et son utilisation en therapie
AU5611701A (en) Agent for the diagnosis and therapy of viral diseases
MXPA02002864A (es) Secuencias de arn de auto- escision y su uso para el control de sintesis de proteinas.
AU2002222308A1 (en) Proteins, genes and their use for diagnosis and treatment of vascular response